Skip to main content
Premium Trial:

Request an Annual Quote

Partners HealthCare System Opts for Agilent Gene Expression Platform

NEW YORK, April 13 (GenomeWeb News) - Agilent Technologies and Partners HealthCare System said today that they have signed a one-year agreement for Agilent to provide microarray and gene expression products to Massachusetts General Hospital and Brigham and Women's Hospital.

Under the terms of the agreement, Agilent will supply the Partners HealthCare Center for Genetics and Genomics (HPCGG) with gene expression instrumentation, including a microarray scanner and a bioanalyzer.

The agreement also determines pricing for Partners HealthCare's hospitals to purchase analytical tools and instruments from Agilent's Life Sciences and Chemical Analysis group, including liquid and gas chromatographs, mass spectrometers, microarrays, microfluidic devices, software, columns, reagents, and other supplies.

Partners HealthCare is the parent organization for MGH and BWH. The HPCGG provides research services to those hospitals as well as McLean Hospital, Newton-Wellesley Hospital, North Shore Medical Center, Partners Community HealthCare, Dana-Farber/Partners CancerCare, and Harvard Clinical Research Institute.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.